Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31672108 | 1.00 | CFTR (0.31) | CFTRPARP1AKR1C3 | |
| SCHEMBL22975145 | 1.00 | CFTR (0.31) | CFTRPARP1AKR1C3 | |
| SCHEMBL22975402 | 0.94 | CFTR (0.31) | CFTR | |
| SCHEMBL22975400 | 0.94 | CFTR (0.31) | CFTR | |
| SCHEMBL26938947 | 0.91 | PARP1 (0.35) | PARP1 | |
| SCHEMBL28765337 | 0.88 | GPR119 (0.33) | CFTRPARP1 | |
| SCHEMBL28765339 | 0.88 | GPR119 (0.33) | CFTRPARP1 | |
| SCHEMBL22975186 | 0.87 | CFTR (0.31) | CFTR | |
| SCHEMBL22975187 | 0.87 | CFTR (0.31) | CFTR | |
| SCHEMBL26939051 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648753-B1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMA (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250248981-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2025-08-07 | — | — | US | disclosed |
| US-12122788-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | disclosed |
| EP-4013741-B1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMA (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-114555556-B | Process for preparing CFTR modulators | 弗特克斯药品有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-12-14 | — | — | US | disclosed |
| US-11591350-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-28 | — | — | US | disclosed |
| US-11584761-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4013763-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-4013741-A1 | PROCESS OF MAKING CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114555556-A | Methods of making CFTR modulators | 弗特克斯药品有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021030554-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030554-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030555-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030555-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047350-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2021-02-18 | — | — | US | disclosed |
| US-20210047345-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | CFTR, SLC26A4, TMEM109 | CFTR 1/4885PARP1 3201/4885AKR1C3 2992/4885 |
| US-20250248981-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | CFTR, TMCO1, ITPR1 | CFTR 1/4885PARP1 3431/4885AKR1C3 3870/4885 |
| US-11584761-B2 | Process of making CFTR modulators | CFTR, SLC26A4, TMEM109 | CFTR 1/4885PARP1 3201/4885AKR1C3 2992/4885 |
| US-11591350-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1G, SCNN1B | CFTR 1/4885PARP1 4791/4885AKR1C3 3130/4885 |
| US-20210047345-A1 | PROCESS OF MAKING CFTR MODULATORS | CFTR, SLC26A4, TMEM109 | CFTR 1/4885PARP1 3201/4885AKR1C3 2992/4885 |
| US-12122788-B2 | Process of making CFTR modulators | CFTR, SLC26A4, TMEM109 | CFTR 1/4885PARP1 3201/4885AKR1C3 2992/4885 |
| US-20210047350-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CFTR 1/4885PARP1 4791/4885AKR1C3 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.